Medexus Pharmaceuticals
TSX:MDP Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
WA
Consensus Narrative from 7 Analysts
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Key Takeaways Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity. Operational efficiencies and a strong financial position support profitability and long-term growth through strategic investments and improved product yields.
View narrativeCA$6.49
FV
55.8% undervalued intrinsic discount9.25%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
3 days ago author updated this narrative